| Date | Title | Description |
| 14.03.2025 | Фармацевтические компании Mallinckrodt и Endo объединятся за почти $7 млрд | Акционеры Endo получат $80 млн наличными и будут владеть 49,9% объединенной компании, в то время как акционеры Mallinckrodt будут владеть оставшейся частью, а стоимость предприятия составит $6,7 млрд, сообщили компании в четверг.
Новая комп... |
| 20.12.2024 | Endo USA, Inc. Issues Voluntary, Nationwide Recall of Adrenalin® Chloride Solution (EPINEPHrine Nasal Solution, USP) Due to the Potential for Administration Errors | Summary
Company Announcement Date: December 20, 2024 FDA Publish Date: December 20, 2024 Product Type: Drugs Reason for Announcement:
Recall Reason Description
Product is an unapproved drug. Company Name: Endo, Inc. Brand Name:
Brand Name(s... |
| 04.12.2024 | Sinclair Announces New Executive Leadership to Support Global Growth Trajectory | Sinclair
Sinclair is excited to announce the appointment of three dynamic leaders to its executive leadership team, marking a pivotal transition in propelling Sinclair into its next phase of growth, innovation, and market leadership. Frank ... |
| 19.11.2024 | Endo Expands Voluntary Recall of Clonazepam Orally Disintegrating Tablets, USP (C-IV) Due to Potential Product Carton Strength Mislabeling | Summary
Company Announcement Date: November 18, 2024 FDA Publish Date: November 19, 2024 Product Type: Drugs Reason for Announcement:
Recall Reason Description
Mislabeled with the incorrect strength on the carton Company Name: Endo, Inc. Br... |
| 29.08.2024 | Endo's Financial Turnaround: A New Chapter in Pharmaceuticals | Endo, Inc. is navigating a stormy sea, but recent financial results suggest it may be charting a course toward calmer waters. The company, based in Malvern, Pennsylvania, has released its second-quarter financial results for 2024, revealing... |
| 27.08.2024 | ENDO ANNOUNCES CEO TRANSITION | Board to Initiate CEO Search Process; Scott Hirsch Appointed as Interim CEO
MALVERN, Pa., Aug. 27, 2024 /PRNewswire/ -- Endo, Inc. (OTCQX: NDOI) ("Endo" or the "Company"), a diversified specialty pharmaceutical company t... |
| 27.08.2024 | ENDO REPORTS SECOND-QUARTER 2024 FINANCIAL RESULTS | Raises 2024 Financial Expectations
Provides 2025 Financial Expectations
MALVERN, Pa., Aug. 27, 2024 /PRNewswire/ -- Endo, Inc. ("Endo" or the "Company") (OTCQX: NDOI), a diversified specialty pharmaceutical company trans... |
| 31.07.2024 | Endo Announces Effectiveness of Form S-1 Registration Statement for Existing Shares | MALVERN, Pa., July 31, 2024 /PRNewswire/ -- Endo, Inc. (OTCQX: NDOI) ("Endo" or the "Company"), a diversified specialty pharmaceutical company transforming insights into life-enhancing therapies, today announced that the... |
| 12.07.2024 | Endo Files Registration Statement with SEC, Advancing Planned Move to NYSE | MALVERN, Pa., July 12, 2024 /PRNewswire/ -- Endo, Inc. (OTCQX: NDOI) ("Endo" or the "Company"), a diversified specialty pharmaceutical company transforming insights into life-enhancing therapies, today announced that it ... |
| 28.06.2024 | Endo Announces Commencement of OTCQX Trading | MALVERN, Pa., June 28, 2024 /PRNewswire/ -- Endo, Inc. (OTCQX: NDOI) ("Endo" or the "Company") today announced that the Company has commenced trading on the OTCQX® Best Market ("OTCQX") under the ticker symbol ... |
| 10.06.2024 | Endo Launches New Dupuytren's Contracture Campaign: Reminders | The campaign aims to embolden patients to become advocates in their treatment journey and find a hand specialist who considers their preferences and lifestyle.
Commercial features real Dupuytren's contracture patients as hand doubles and co... |
| 15.05.2024 | Endo to Announce First-Quarter 2024 Financial Results for Endo International plc | MALVERN, Pa., May 15, 2024 /PRNewswire/ -- Endo, Inc. ("Endo" or the "Company"), a newly formed entity that recently acquired substantially all of the assets of Endo International plc ("EIP") as contemplated by... |
| 07.05.2024 | Endo Announces New Peyronie's Disease Data Presented at the American Urological Association Annual Meeting | MALVERN, Pa., May 7, 2024 /PRNewswire/ -- Endo, Inc. announced today that three new presentations related to Peyronie's disease and XIAFLEX® (collagenase clostridium histolyticum) were shared during the American Urological Association (AUA)... |
| 06.05.2024 | Endo Launches Enhanced TruDelivery® Ready-to-Use Product Line and Platform | MALVERN, Pa., May 6, 2024 /PRNewswire/ -- Endo, Inc. announced today that its Endo Injectable Solutions business unit launched its enhanced ready-to-use product line and platform, TruDelivery®, underscoring the company's commitment to build... |
| 23.04.2024 | Endo, Inc. Completes Acquisition of Endo International plc's Assets | Newly Formed Company Poised for Sustained Growth With a Strengthened Balance Sheet, Resolved Litigation Overhang, Diversified Portfolio of Medicines and a Deep New Product Pipeline
MALVERN, Pa., April 23, 2024 /PRNewswire/ -- Endo, Inc. (&q... |
| 11.04.2024 | Endo, Inc. Announces Pricing of $1.5 billion of Senior Secured Term Loan as Part of Endo's $2.5 billion Exit Financing | MALVERN, Pa., April 11, 2024 /PRNewswire/ -- Endo, Inc. ("Endo"), a newly formed entity, today announced that its wholly-owned subsidiary Endo Finance Holdings, Inc. (the "Borrower") priced its $1,500.0 million senior se... |
| 04.04.2024 | Lupin appoints Dr Ranjana Pathak as Chief Quality Officer | Drugmaker Lupin Limited has appointed Dr Ranjana Pathak as Chief Quality Officer, succeeding Johnny Mikell who will be retiring, the company said.
With over three decades of industry experience, Pathak will oversee all aspects of quality an... |
| 01.04.2024 | Endo, Inc. Announces Proposed New Senior Secured Credit Facilities | MALVERN, Pa., April 1, 2024 /PRNewswire/ -- Endo, Inc. ("Endo"), a newly formed entity, today announced that its wholly-owned subsidiary Endo Finance Holdings, Inc. (the "Borrower") intends to enter into new senior secur... |
| 05.03.2024 | Strides Pharma receives USFDA approval for neurology medication Gabapentin | Strides Pharma Science Limited (Strides) has received approval of Gabapentin Tablets USP, in strengths of 600 mg and 800 mg, by the United States Food & Drug Administration (USFDA). This announcement is a step towards expanding Strides'... |
| 04.03.2024 | Biopharmaceutical Innovations Lead the Way in Migraine Drugs Market Advancement | CAGR of 3.1% | Migraine is a clinical condition associated with painful headaches and other symptoms such as nausea, sensitivity to smell, and others.
PORTLAND, OREGON, UNITED STATES, March 4, 2024 /EINPresswire.com/ -- Migraine drugs are medications that... |
| 13.03.2023 | Endo Provides Top-Line Results from Phase 2 Study of Collagenase Clostridium Histolyticum (CCH) in Participants With Plantar Fibromatosis | DUBLIN, March 13, 2023 /CNW/ -- Endo International plc ENDPQ today announced top-line results from its Phase 2 clinical study of collagenase clostridium histolyticum (CCH) in participants with plantar fibromatosis. While the primary endpoin... |
| 25.10.2021 | Endo International : Announces First-Ever XIAFLEX® (collagenase clostridium histolyticum) Television Commercial, Bent Carrot, and Branded Campaign to Raise Awareness of Peyronie's Disease | DUBLIN, Oct. 25, 2021 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) announced today the launch of their first-ever XIAFLEX® (collagenase clostridium histolyticum) television commercial, Bent Carrot. The spot introduces men to XIAFLE... |
| 10.09.2021 | Endo Settles New York State Opioid Cases and Provides Update on Remaining Opioid Litigation | Endo International plc announced that it and its wholly-owned subsidiaries, Endo Health Solutions Inc., Endo Pharmaceuticals Inc., Par Pharmaceutical, Inc. and Par Pharmaceutical Companies, Inc., have settled three consolidated cases pendin... |
| 04.08.2021 | Endo Announces Execution of Definitive Settlement Agreement and Release Resolving Tennessee State Court Case | |
| 22.07.2021 | Endo Announces Agreement in Principle to Settle Tennessee State Court Case | |
| 06.05.2021 | ENDO INTERNATIONAL PLC
Endo International : Reports First-Quarter 2021 Financial Results And Updates 2021 Financial Guidance | DUBLIN, May 6, 2021 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) today reported financial results for the first-quarter ended March 31, 2021.
"I am proud of the continued strong execution across each of Endo's business segment... |
| 13.04.2021 | Endo Announces Publication of Phase 3 Qwo® (collagenase clostridium histolyticum-aaes) Data in Peer-Reviewed Dermatologic Surgery | |
| 11.03.2021 | Endo International plc Announces Pricing of Private Offering Of Senior Secured Notes | |
| 11.03.2021 | Endo International plc Announces Proposed Private Offering Of Senior Secured Notes | |
| 05.01.2021 | Endo Announces Licensing Agreement for Paladin Labs Inc. to Commercialize Abaloparatide in Canada | |
| 18.11.2020 | Endo Announces Expiration Of Hart-Scott-Rodino Waiting Period For BioSpecifics Tender Offer | |
| 05.11.2020 | Endo Announces Strategic Actions to Further Position the Company for Long-Term Success | |
| 19.10.2020 | Endo to Acquire BioSpecifics to Enhance Profitability of XIAFLEX® and Qwo™ | |
| 05.07.2017 | Advent International to Buy SOMAR for $124M | Endo International plc (NASDAQ: ENDP) today announced it has entered into a definitive agreement to sell Mexico City based Grupo Farmacéutico SOMAR to Advent International for approximately $124 million subject to customary adjustments for ... |
| 05.07.2017 | Advent International to Buy SOMAR for $124M | Endo International plc (NASDAQ: ENDP) today announced it has entered into a definitive agreement to sell Mexico City based Grupo Farmacéutico SOMAR to Advent International for approximately $124 million subject to customary adjustments for ... |
| 31.03.2016 | FTC sues Endo Pharmaceuticals for paying off generic drugmakers – and delaying market entry | These kinds of settlements “harm consumers twice,” FTC Chairwoman Edith Ramirez said in a statement. Not only does it take longer for patients to receive more cost-effective therapies, but it prevents generic competition in the market.
The ... |
| 23.04.2014 | Frenzy of pharma deals resembles 2008, but goal is leaner, more focused businesses | Between Pfizer and AstraZeneca deal rumors followed by a strategic portfolio exchange by GlaxoSmithKline and Novartis and an offer for Allergan this week, it feels like a deal frenzy is underway. When you look at the numbers from the first ... |
| 19.02.2014 | Endo Health takes $500M writedown on American Medical Systems | Endo Health Solutions (NSDQ:ENDP) said today that it plans to write down the value of its American Medical Systems acquisition.
The subsidiary has become embroiled in a spate of product liability lawsuits filed over its pelvic mesh products... |
| 07.01.2014 | Cambridge Endo closes $3M round | Cambridge Endoscopic Devices closed a debt and options offering after meeting it $2.9 million target for the round.
Framingham, Mass.-based Cambridge Endo makes medical devices used for single-incision laparoscopy procedures.
The company se... |
| 05.12.2012 | How to solve the puzzle of end-to-end care? Just ask Endo Health Solutions | “There is no growth in duplication,” McHugh said. “Growth is in the gaps where patient need and company opportunity intersects.”
That led Endo to look at diagnostics, devices and health services in the area of urology — the company already ... |
| 02.10.2012 | Early stage companies join Philly life science and tech venture summit this year | Steve Case, the former CEO and co-founder of AOL and founder of investment firm Revolution, will be a keynote speaker for the conference. Case was selected by President Barack Obama to serve as chairman of the Startup America Partnership, a... |
| 24.07.2012 | Chronic pain drug developer for cancer, lower back pain raises $3M | Location: Blue Bell, Pennsylvania
Industry: Pharmaceuticals
Solution/product: Its lead product is chronic pain treatment LevoCap, a proprietary once-a-day extended release dosage form of the opioid levorphanol. It is being presented as an a... |
| 17.07.2012 | Par Pharmaceuticals’ generic appeal attracts $1.9 billion private equity offer | There has been quite a bit of crossover between generic and branded pharmaceutical companies with the likes of Watson and Teva keen to have the profitability that accompanies a successful branded drug with patent exclusivity lasting years i... |
| 04.05.2012 | 7 things to consider for your company’s social media policy | Plan for a crisis. You will have one. Companies need to develop social media policies in order to be sufficiently prepared to respond when things happen. Comments can be picked up and spread so fast on the Internet that companies have a ver... |
| 17.04.2012 | Patent award to BDSI triggers $15M milestone payment from Endo Pharma | The USPTO had signaled earlier this year that it would issue a patent for the technology. In February, the patent office issued a notice of allowance, which means that a review found the application meets all the requirements for a patent.
... |
| 16.02.2012 | BDSI to get patent; issuance triggers $15M milestone from partner Endo | The milestone payment will be coming from drug partner Endo Pharmaceuticals (NASDAQ:ENDP). Raleigh, North Carolina-based BDSI and Endo last month entered a development and commercialization deal that could pay BDSI up to $180 million upon s... |
| 06.02.2012 | $40M stock offering filed by BioDelivery Sciences International | The Endo deal, which gave BDSI $30 million up front, secures a partner responsible for the phase 3 trials and commercialization of BEMA Buprenorphine. That frees BDSI to devote its attention and its financial resources to the rest of its dr... |
| 14.11.2011 | Endo Pharmaceuticals ends development of drug for growth hormone condition | Additionally, Endo discontinued development of the octreotide implant for the treatment of carcinoid syndrome because market research found it faced commercial challenges with physician acceptance and the expected rate of existing patients ... |
| 22.06.2011 | Endo closes the deal with American Medical Systems for $2.9 billion in cash | Endo Pharmaceuticals Holdings Inc. (NSDQ:ENDP), once devoted solely to the drug market, began its foray into medical devices with a successful $2.9 billion cash buyout of American Medical Systems Holdings Inc. (NSDQ:AMMD).
Endo paid $30 per... |
| 04.04.2011 | Invacare hires chief compliance officer | The company stressed at the time that it fully stands behind the safety of its products. “The FDA warning letter does not state that our products are unsafe, nor has it impacted our production,” CEO Gerald Blouch said. “The letter is relate... |
| 09.12.2009 | Shop Talk: Interphase Systems CEO John Biglin on Ready-IT BioPharma | A year ago, John Biglin, the CEO of Interphase Systems, was talking to the CFO of an emerging Center City pharmaceutical company.
The CFO, intent on keeping in order the financial house of his blue-chip invested life sciences startup, had a... |
| - | $40M stock offering filed by BioDelivery Sciences International | A month after licensing a clinical-stage chronic pain treatment to Endo Pharmaceuticals (NASDAQ:ENDP) in a deal worth up to $180 million, BioDelivery Sciences International (NASDAQ: BDSI) is now preparing an additional $40 million financial... |
| - | How to solve the puzzle of end-to-end care? Just ask Endo Health Solutions | They say knowing is half the battle.
Recognizing these three mantras was the first step that helped Endo Pharmaceuticals (NASDAQ:ENDP) transform itself from a pharmaceuticals company to Endo Health Solutions, a provider of drugs, devices an... |
| - | Par Pharmaceuticals’ generic appeal attracts $1.9 billion private equity offer | Generics producer Par Pharmaceuticals (NYSE: PRX) has been snapped up by a global private equity firm TPG in a deal that values the company at $1.9 billion, the tenth largest deal for the year to date, according to data from Dealogic. Par m... |
| - | FTC sues Endo Pharmaceuticals for paying off generic drugmakers – and delaying market entry | It’s a lucrative thought to a drugmaker with branded drugs and patent-based revenues: Pay off encroaching generic competitors to delay their products from hitting the market. But turns out, this can get sued.
The Federal Trade Commission ha... |
| - | Patent award to BDSI triggers $15M milestone payment from Endo Pharma | A drug delivery technology patent awarded to BioDelivery Sciences International (NASDAQ:BDSI) has triggered a $15 million milestone payment from drug partner Endo Pharmaceuticals (NASDAQ:ENDP).
Raleigh, North Carolina-based BDSI said today ... |
| - | 7 things to consider for your company’s social media policy | Pharmaceutical and medical device companies seem to view social media with the alternating fascination and horror of watching American Idol. But even if they have no wish to participate, companies still need to craft a social media policy a... |
| - | Chronic pain drug developer for cancer, lower back pain raises $3M | Company name: Relmada Therapeutics
Location: Blue Bell, Pennsylvania
Industry: Pharmaceuticals
Solution/product: Its lead product is chronic pain treatment LevoCap, a proprietary once-a-day extended release dosage form of the opioid levorph... |
| - | BDSI to get patent; issuance triggers $15M milestone from partner Endo | BioDelivery Sciences International (NASDAQ:BDSI) stands to gain a $15 million milestone payment after getting word that its drug delivery technology will be granted a patent for two drug treatments.
The U.S. Patent and Trademark Office has ... |
| - | Frenzy of pharma deals resembles 2008, but goal is leaner, more focused businesses | Between Pfizer and AstraZeneca deal rumors followed by a strategic portfolio exchange by GlaxoSmithKline and Novartis and an offer for Allergan this week, it feels like a deal frenzy is underway. When you look at the numbers from the first ... |
| - | Endo Pharmaceuticals ends development of drug for growth hormone condition | Endo Pharmaceuticals (NASDAQ:ENDP) has ended its developments of an octreotide implant to treat a disorder in which the body produces too much growth hormone following a review of its research and development priorities, according to a fili... |
| - | Early stage companies join Philly life science and tech venture summit this year | A long-running venture investment summit in Philadelphia will include presentations from early stage companies for the first time.
This will supplement the growth stage companies presenting at the Greater Philadelphia Alliance for Capital a... |
| - | Invacare hires chief compliance officer | Home health equipment maker Invacare (NYSE:IVC) has hired a chief compliance officer who previously held the role with Endo Pharmaceuticals (NASDAQ:ENDP).
Colleen Craven’s role will be to ensure that Invacare is compliant with “relevant law... |
